And in some patients, it was found that TNFα therapy would lose its efficacy with prolonged treatment time, or need to be increased in dosage or in combination with other drugs, and after switching to secukinumab, significant results were achieved, so secukinumab may be an effective treatment option for patients with ACH who have failed conventional therapies. This evidence concerns the gene TNF and achondroplasia.